Related references
Note: Only part of the references are listed.Biomarkers in early clinical trials: The committed and the skeptics
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2008)
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort
Ben S. Witmer et al.
CLINICAL CANCER RESEARCH (2008)
Detection of mutations in EGFR in circulating lung-cancer cells
Shyamala Maheswaran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Commercialized multigene predictors of clinical outcome for breast cancer
Jeffrey S. Ross et al.
ONCOLOGIST (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
New technologies around biomarkers and their interplay with drug development
Frank Dieterle et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Trends in the use and role of biomarkers in phase I oncology trials
Bernardo H. L. Goulart et al.
CLINICAL CANCER RESEARCH (2007)
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
J. B. Singer et al.
LEUKEMIA (2007)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach
Torsten Haferlach et al.
ANNALS OF HEMATOLOGY (2007)
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
[Anonymous]
LANCET ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
Feng R. Luo et al.
CLINICAL CANCER RESEARCH (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The AmpliChip (TM) CYP450 Genotyping Test - Integrating a new clinical tool
Jose de Leon et al.
MOLECULAR DIAGNOSIS & THERAPY (2006)
Proteasome inhibition with bortezomib (PS-341): A phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
AL Hamilton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Reanalysis of cancer drugs: Old drugs, new tricks
GFV Woude et al.
CLINICAL CANCER RESEARCH (2004)
Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: Multiinstitutional laboratory trial
P Bolufer et al.
CLINICAL CHEMISTRY (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
